Hims & Hers Deepens Personalized Care Through Platform Expansion
HIMS broadens beyond telehealth, adding labs, new hormone programs and global expansion as it builds a personalized care platform.
HIMS - Hims & Hers Health, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$26.27
DETAILS
HIGH:
$60.00
LOW:
$12.50
MEDIAN:
$24.50
CONSENSUS:
$26.27
UPSIDE:
10.61%
Stock News
Hims offers Apotex's generic semaglutide in Canada after Novo patent expiry
Hims & Hers Health said on Thursday it is now offering Canadians with type 2 diabetes a generic version of semaglutide, the active ingredient in Novo Nordisk's blockbuster drug Ozempic, through its platform.
Hims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform in Canada. This is Hims & Hers' first international generic GLP-1 offering, demonstrating the company's ability to meet the unique needs of each global market it serves while continuing its international expansion efforts. Personalized treatment plans are available starting at $149 CAD/month, making.
Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada
TORONTO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform for eligible customers in Canada. This makes affordable GLP-1 treatment accessible to Canadians for whom cost has long been a barrier to treatment. For eligible customers, personalised treatment plans are available starting at $149/month CAD. GLP-1 treatments have transformed obesity and metabolic health, with.
Hims & Hers: Wegovy Deal Fuels Growth
Hims & Hers, Inc. (HIMS) stock has risen 41% since my last update, driven by product and international expansion. Q1 revenue reached $608 million, up 4% YoY, with U.S. operations declining but international revenue surging 969% to $78 million. The U.S. segment faced tough comps due to prior GLP-1 sales and shipping cadence, while international growth was fueled by ZAVA and Livewell acquisitions.
Hims & Hers Massive Stock Drop Explained
Raising debt increases the risk in Hims and Hers' stock.
Hims & Hers Prices Upsized $350 Million Convertible Notes Offering
Hims and Hers Health (HIMS) has priced a larger $350 million private offering of 0.00% convertible senior notes due 2032, up from the previously announced $300 mi
Hims & Hers Stock Stabilizes After Upsized $350 Million Convertible Note Offering
Hims & Hers Health Inc (NYSE:HIMS) shares are trading flat during Tuesday's pre-market session as traders continue to digest the company's convertible notes offering.
Hims & Hers Health, Inc. Prices Upsized $350 Million Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced the pricing of its offering of $350 million aggregate principal amount of 0.00% convertible senior notes due 2032 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced of.
Hims & Hers Falls on Planned $300 Million Convertible Debt Offering
Hims and Hers Health (HIMS, Financials) fell after the company proposed a private offering of $300 million in convertible senior notes due 2032.The company said p
Forget Hims. Its CEO Dumped 436,000 Shares Before a 1,266% Earnings Miss.
Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector's short history, and bargain hunters are circling the wreckage.
7 Healthcare AI Stocks Under $50 With Huge Upside Potential
Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing.
Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced its intention to offer, subject to market and other conditions, $300 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Hims & Hers also expects to grant.
Hims & Hers Health: GLP-1 Drama Ending Signals Return To Growth
Hims & Hers Health has returned to growth mode after volatility from the GLP-1 transition, yet trades near multi-year lows. The online health platform guided up 2026 revenues to $3B, exceeding consensus, and does not yet reflect the Eucalyptus acquisition. The company faces short-term margin pressure from branded GLP-1 drugs and international scaling, but the long-term target remains at least 20% EBITDA margins in 2030.
DOCS vs. HIMS: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical Info Systems sector have probably already heard of Doximity (DOCS) and Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best option for those looking for undervalued stocks?
HIMS Stock Dips 14.3% Since Q1 Earnings: Should You Still Hold or Sell?
Hims & Hers faces profit pressure in first-quarter 2026, though subscribers increase and a Novo Nordisk GLP-1 partnership broadens weight-loss care.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers Health: The Stock Is On Sale, Buy It
Hims & Hers Health delivered a misunderstood Q1-26, raising FY-26 guidance and reaffirming 2030 revenue and EBITDA targets despite negative sentiment. The transition from compounded to branded GLP-1s pressured margins, but normalized gross margins remain robust and marketing spend is a lever for profitability. Subscriber growth is poised to reaccelerate, with expectations of 100k new weight loss subscribers per month via the Novo partnership, supporting a 30–35% YoY increase.
Hims & Hers Stock Drops After Earnings: Buying Opportunity or Warning Sign?
Hims and Hers continues growing rapidly, but shrinking margins and rising costs are beginning to test the company's long-term profitability story.
Is Hims and Hers Health Stock a Buy After Its Latest Dip?
Hims upped its revenue forecast but is seeing major margin compression. The company could potentially have a big opportunity with peptides, pending the lifting of an FDA ban.
Price Targets
Hims & Hers price target raised to $23 from $18 at Truist
$23.00
(was $23.88)
UBS
Hims & Hers price target lowered to $24.50 from $25.50 at Jefferies
$24.50
(was $25.28)
Jefferies
Hims & Hers price target raised to $35 from $30 at Needham
$35.00
(was $25.22)
UBS
Hims & Hers price target raised to $32 from $30 at Canaccord
$32.00
(was $29.14)
Canaccord Genuity
Hims & Hers price target lowered to $25 from $28 at Deutsche Bank
$25.00
(was $26.19)
George Hill
·
Deutsche Bank
Hims & Hers price target raised to $28 from $25 at Deutsche Bank
$28.00
(was $23.47)
Deutsche Bank
Needham Upgrades Hims and Hers (HIMS) to Buy
$30.00
(was $22.35)
Ryan MacDonald
·
Needham
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS) amid Novo partnership
$12.50
(was $21.58)
Oppenheimer
Hims & Hers price target lowered to $25 from $48 at Barclays
$25.00
(was $15.90)
Barclays
Hims & Hers price target lowered to $21 from $40 at Morgan Stanley
$21.00
(was $14.38)
Craig Hettenbach
·
Morgan Stanley
Hims & Hers price target lowered to $24 from $33 at Evercore ISI
$24.00
(was $14.10)
Evercore ISI
Hims & Hers price target lowered to $18 from $37 at Truist
$18.00
(was $15.51)
Jailendra Singh
·
Truist Financial
Hims & Hers price target lowered to $17.50 from $20 at Leerink
$17.50
(was $15.51)
Leerink Partners
Hims & Hers price target lowered to $31 from $42 at Deutsche Bank
$31.00
(was $18.25)
George Hill
·
Deutsche Bank
Hims and Hers (HIMS) PT Lowered to $20 at Leerink Partners
$20.00
(was $17.35)
Michael Cherny
·
Leerink Partners
Hims & Hers price target lowered to $60 from $85 at BTIG
$60.00
(was $27.09)
BTIG
Hims and Hers (HIMS) PT Lowered to $29 at BofA Securities, 'Sales and EBITDA margin expectations are too high'
$29.00
(was $35.46)
Wolfe Research
Hims & Hers initiated with an Overweight at Barclays
$48.00
(was $39.12)
Barclays
Hims and Hers (HIMS) PT Lowered to $41 at Leerink Partners
$41.00
(was $40.23)
Michael Cherny
·
Leerink Partners
Morgan Stanley on Hims and Hers (HIMS): 'October Data Continues to Trend in the Wrong Direction'
$40.00
(was $39.75)
Craig Hettenbach
·
Morgan Stanley